Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
16 participants
INTERVENTIONAL
2011-10-31
2011-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluate Efficacy and Safety Of Tolterodine Extended Release Capsule Compared With Tolterodine Immediate Release Tablet
NCT00139724
Tolterodine Drug Use Investigation.(Post Marketing Commitment Plan)
NCT01488578
A Study to Evaluate the Efficacy of Tolterodine on Specific Symptoms in Adult Patients With Overactive Bladder.
NCT00645281
A Study to Test the Effects of Tolterodine Tartrate in Patients With Overactive Bladder (0000-107)
NCT00768521
Exploring Predictors of Symptoms Relapse After Discontinuation of Treatment in Overactive Bladder (OAB) Patients
NCT00730535
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A
4 mg tolterodine extended release capsules, administered with water and under fasting condition.
tolterodine tartrate
4 mg single dose of extended release capsules
B
4 mg microspheres in powder blend release rate 2 (MPB-RR2), administered without water and under fasting condition.
tolterodine tartrate
4 mg single dose of microspheres in powder blend
C
4 mg microspheres in powder blend release rate 1 (MPB-RR1), administered without water and under fasting condition.
tolterodine tartrate
4 mg single dose of microspheres in powder blend
D
4 mg MPB-RR1, administered without water and under fed condition.
tolterodine tartrate
4 mg single dose of microspheres in powder blend
E
4 mg MPB-RR1, administered with water and under fasting condition.
tolterodine tartrate
4 mg single dose of microspheres in powder blend
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
tolterodine tartrate
4 mg single dose of extended release capsules
tolterodine tartrate
4 mg single dose of microspheres in powder blend
tolterodine tartrate
4 mg single dose of microspheres in powder blend
tolterodine tartrate
4 mg single dose of microspheres in powder blend
tolterodine tartrate
4 mg single dose of microspheres in powder blend
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
21 Years
55 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Singapore, , Singapore
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A6121196
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.